Abstract Archives of the RSNA, 2013
Patrick Veit-Haibach MD, Presenter: Research Grant, Bayer AG
Research Grant, Siemens AG
Nik Hauser MD, Abstract Co-Author: Nothing to Disclose
Bianca Chilla MD, Abstract Co-Author: Nothing to Disclose
Gustav K. Von Schulthess MD, PhD, Abstract Co-Author: Consultant, ICON plc
Grant, General Electric Company
Speaker, General Electric Company
Rahel A. Kubik-Huch MD, Abstract Co-Author: Nothing to Disclose
To assess and to compare the diagnostic accuracy of PET/CT and PET/MRI in primary and metastatic gynaecological malignancies.
13 patients (13 female, mean age: 64, range 55-76years) with different primary and recurrent gynaecological diseases underwent a contrast-enhanced tri-modality PET/CT-MRI examination (PET/CT D 690 and 3T MRI 750W, GE Healthcare). Patients were first injected with an average of 320 MBq F18-FDG and then rested for 30 minutes. Then, a full diagnostic, contrast-enhanced MRI of the abdomen and pelcis, based on the current guidelines, was acquired with the following sequences: coronal T2 SSFSE pelvis, axial T2 SSFSE liver, axial T1 LaveFlex whole abdomen, axial diffusion pelvis, sagittal/axial T2 propeller pelvis, sag/axial T1 LavaFlex post contrast whole abomden. After the MRI, patients were transferred on a dedicated shuttle to the PET/CT. Here, a standard PET/CT with /without intravenous contrast media was acquired (FOV mid-thigh to the vertex of the skull. CT: 50-79 mAs/slice, automated dose modulation 120 kVp, 3.75 mm slice thickness. PET: 3D mode, 2 minutes/bed, iterative reconstruction with 3 iterations, 18 subsets). All data were evaluated on a commercially available workstation and can be displayed as PET, CT, PET/CT and PET/MRI. PET/MRI and PET/CT were evaluated concerning detection and conspicuity of the primary tumor, lymph node metastases and distant metastases. Readers also evaluated if the PET/MRI revealed relevant additional information compared to PET/CT.
Acquisition of PET/CT-MRI and PET/CT vs. PET/MRI evaluation was feasible in all patients. Concerning the primary tumour, the PET/CT was superior in 2 cases, PET/MRI in 5 cases, concerning lymph nodes PET/CT was superior in 2 cases, PET/MRI in 2 cases, in abdominal metastases PET/CT was superior in 2 cases, PET/MRI in none. PET/CT overall showed additional relevant additional information in 9 cases mainly concerning distant metastases, while PET/MRI showed relevant additional information in 3 cases concerning the primary tumour.
PET/MRI is well feasible within a tri-modality PET/CT-MRI system. The PET/MRI shows mainly advantages concerning the evaluation of the pimary tumor/local pelvic situation while the PET/CT has advantages concerning distant metastases.
PET/MRI might be eligible to replace PET/CT in the work-up of OB-Gyn cancers.
Veit-Haibach, P,
Hauser, N,
Chilla, B,
Von Schulthess, G,
Kubik-Huch, R,
Diagnostic Accuracy of PET/MRI in Gynaecological Malignancies: Initial Results. Radiological Society of North America 2013 Scientific Assembly and Annual Meeting, December 1 - December 6, 2013 ,Chicago IL.
http://archive.rsna.org/2013/13027418.html